Eledon Receives FDA Orphan Drug Designation for Tegoprubart
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy ELDN?
Eledon Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has granted Orphan Drug designation, ODD, to tegoprubart for the prevention of allograft rejection in liver transplantation. "Clinical studies in kidney transplantation have demonstrated that tegoprubart has the potential to improve graft survival and function while reducing the side effects associated with calcineurin inhibitors, supporting its promise as a novel immunosuppressive therapy across multiple organ transplant settings," said David-Alexandre C. Gros, MD, Chief Executive Officer of Eledon. "Based on the encouraging preclinical evidence we have generated to date, we believe liver transplantation represents a significant incremental opportunity for tegoprubart, and we look forward to evaluating its potential in the clinical setting through an anticipated investigator sponsored trial initiating later this year."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ELDN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ELDN
Wall Street analysts forecast ELDN stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 2.900
Low
4.00
Averages
7.75
High
10.00
Current: 2.900
Low
4.00
Averages
7.75
High
10.00
About ELDN
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. Tegoprubart is engineered to potentially both improve safety and provides pharmacokinetic, pharmacodynamic, and dosing advantages. CD40L is primarily expressed on activated CD4+ T cells, platelets, and endothelial cells while the CD40 receptor is constitutively expressed on antigen-presenting cells, such as macrophages and dendritic cells, as well as B cells.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eledon Pharmaceuticals Receives FDA Orphan Drug Designation
- FDA Orphan Drug Designation: Eledon Pharmaceuticals' lead candidate, tegoprubart, has received Orphan Drug designation from the FDA, which is expected to provide a crucial treatment option for preventing allograft rejection in liver transplantation, enhancing the company's competitive position in the biotech sector.
- Market Opportunity Assessment: CEO David-Alexandre Gros stated that based on encouraging preclinical evidence, liver transplantation represents a significant incremental market opportunity for tegoprubart, potentially driving future revenue growth for the company.
- Clinical Trial Plans: The company anticipates initiating an investigator-sponsored trial later this year to further validate the efficacy and safety of the antibody therapy, aiming to expedite the product's market entry.
- Regulatory Incentives: The FDA's Orphan Drug designation offers Eledon multiple regulatory advantages, including tax credits for clinical trial costs and waivers for marketing application user fees, along with up to seven years of U.S. marketing exclusivity, significantly enhancing the company's commercial outlook.
See More
Eledon Pharmaceuticals Receives FDA Orphan Drug Designation for Tegoprubart
- Orphan Drug Designation: Eledon Pharmaceuticals announced that its drug tegoprubart has received FDA orphan drug designation aimed at preventing allograft rejection in liver transplantation, which opens new market opportunities for the company in this critical area.
- Clinical Trial Plans: CEO David-Alexandre Gros stated that based on the encouraging preclinical evidence generated so far, Eledon plans to initiate an investigator-sponsored clinical trial later this year to evaluate the potential of tegoprubart in liver transplantation.
- Positive Market Reaction: In pre-market trading on NasdaqCM, Eledon shares rose by 6.9% to $3.1, reflecting a positive market sentiment regarding the drug's prospects, which may attract more investor interest.
- Multiple Designation Background: Notably, tegoprubart has previously received orphan drug designation for preventing allograft rejection in pancreatic islet cell transplantation and for treating amyotrophic lateral sclerosis, indicating its potential across multiple indications.
See More
NewcelX Collaborates with Eledon to Advance Diabetes Treatment
- Collaborative Research Agreement: NewcelX has signed a collaborative research agreement with Eledon to integrate its lead product NCEL-101 with Eledon's anti-CD40L monoclonal antibody tegoprubart, aiming to advance a functional cure for Type 1 Diabetes, marking a significant advancement in diabetes treatment.
- Integration of Clinical Experience: Eledon's clinical experience with over 100 transplant patients will provide crucial clinical data and insights for the development of NCEL-101, potentially streamlining the regulatory pathway and accelerating the product's market entry.
- Enhanced Immune Modulation: The immune modulation component of NCEL-101 is designed to improve cell durability and graft survival, with expectations to match outcomes seen with donor human islets, thereby enhancing treatment efficacy and addressing market demand for functional insulin-producing cells.
- Strategic Milestone: NewcelX's Chief Scientific Officer stated that this collaboration not only enhances the company's clinical execution capabilities but also broadens partnerships with leaders in immune biology and transplant medicine, which is expected to accelerate clinical project advancement and increase visibility among investors.
See More
NewcelX Collaborates with Eledon to Advance Diabetes Treatment
- Collaborative Research Agreement: NewcelX has signed a collaboration agreement with Eledon to integrate its lead product NCEL-101 with Eledon's anti-CD40L monoclonal antibody tegoprubart, aiming to advance a functional cure for Type 1 Diabetes, which is expected to accelerate clinical timelines and optimize regulatory pathways.
- Integration of Clinical Experience: Eledon's clinical experience with over 100 transplant patients provides crucial data support for the development of NCEL-101, which not only enhances the efficacy of cell replacement therapies but may also streamline the regulatory approval process, thereby expediting the product's market entry.
- Core Product Positioning: NCEL-101, as NewcelX's core therapeutic product, aims to address the shortage of functional insulin-producing cells through scalable, off-the-shelf manufacturing, with the integration of immune modulation intended to enhance cell survival and durability, thereby improving treatment outcomes.
- Strategic Milestone: NewcelX's Chief Scientific Officer Michel Revel stated that this collaboration marks an important strategic milestone for the company in executing clinical programs, and is expected to enhance partnerships with leaders in immune biology and transplant medicine, ultimately driving long-term shareholder value.
See More
Eledon Pharmaceuticals Presents 24-Month Data on Tegoprubart, Showing Significant eGFR Improvement
- Clinical Trial Results: Eledon presented 24-month follow-up data from eight patients at the 2026 American Society of Transplant Surgeons Winter Symposium, showing a significant increase in eGFR from 67.0 mL/min/1.73 m² at 12 months to 74.2 mL/min/1.73 m², indicating the potential efficacy of tegoprubart in kidney transplantation.
- Safety Assessment: Throughout the study, there were no episodes of biopsy-proven acute rejection, graft loss, death, or new-onset diabetes, further validating the safety and tolerability of tegoprubart, which enhances its market prospects.
- Academic Presentation Schedule: The study's poster will be presented during the poster session on January 23, 2026, from 5:45 to 7:15 PM, providing attendees with an opportunity to gain deeper insights into the drug, potentially attracting investor interest.
- Company Background: Eledon is a clinical-stage biotechnology company focused on developing immune-modulating therapies, with tegoprubart as its lead candidate, targeting CD40L's high affinity, which offers broad therapeutic potential in areas such as kidney transplantation.
See More
Avant Technologies Achieves 83% Insulin Independence Rate, Driving Investment Shift
- Clinical Trial Success: Avant Technologies achieved an 83% insulin independence rate in recent clinical trials, marking a significant shift towards functional cures that has attracted investment interest from the pharmaceutical industry, driving record valuations in 2025 M&A activity.
- Massive Market Potential: Analysts project the regenerative medicine market will surge from $37.98 billion in 2025 to $88.85 billion by 2030, highlighting strong demand for curative cell therapies, with Avant Technologies positioned at the forefront of this growth wave.
- Technological Breakthrough: Avant's collaboration with SGAustria to develop cell encapsulation technology protects genetically modified insulin-producing cells from immune rejection, addressing the long-standing issue of patients' reliance on immunosuppressive drugs, thereby enhancing treatment safety and efficacy.
- Global Health Market Opportunity: With 589 million people globally living with type 1 and insulin-dependent type 2 diabetes, projected to reach 853 million by 2050, Avant's technology is poised to capture a significant share of this vast market, driving future growth for the company.
See More
Eledon Pharmaceuticals Receives FDA Orphan Drug Designation
- FDA Orphan Drug Designation: Eledon Pharmaceuticals' lead candidate, tegoprubart, has received Orphan Drug designation from the FDA, which is expected to provide a crucial treatment option for preventing allograft rejection in liver transplantation, enhancing the company's competitive position in the biotech sector.
- Market Opportunity Assessment: CEO David-Alexandre Gros stated that based on encouraging preclinical evidence, liver transplantation represents a significant incremental market opportunity for tegoprubart, potentially driving future revenue growth for the company.
- Clinical Trial Plans: The company anticipates initiating an investigator-sponsored trial later this year to further validate the efficacy and safety of the antibody therapy, aiming to expedite the product's market entry.
- Regulatory Incentives: The FDA's Orphan Drug designation offers Eledon multiple regulatory advantages, including tax credits for clinical trial costs and waivers for marketing application user fees, along with up to seven years of U.S. marketing exclusivity, significantly enhancing the company's commercial outlook.
See More
Eledon Pharmaceuticals Receives FDA Orphan Drug Designation for Tegoprubart
- Orphan Drug Designation: Eledon Pharmaceuticals announced that its drug tegoprubart has received FDA orphan drug designation aimed at preventing allograft rejection in liver transplantation, which opens new market opportunities for the company in this critical area.
- Clinical Trial Plans: CEO David-Alexandre Gros stated that based on the encouraging preclinical evidence generated so far, Eledon plans to initiate an investigator-sponsored clinical trial later this year to evaluate the potential of tegoprubart in liver transplantation.
- Positive Market Reaction: In pre-market trading on NasdaqCM, Eledon shares rose by 6.9% to $3.1, reflecting a positive market sentiment regarding the drug's prospects, which may attract more investor interest.
- Multiple Designation Background: Notably, tegoprubart has previously received orphan drug designation for preventing allograft rejection in pancreatic islet cell transplantation and for treating amyotrophic lateral sclerosis, indicating its potential across multiple indications.
See More
NewcelX Collaborates with Eledon to Advance Diabetes Treatment
- Collaborative Research Agreement: NewcelX has signed a collaborative research agreement with Eledon to integrate its lead product NCEL-101 with Eledon's anti-CD40L monoclonal antibody tegoprubart, aiming to advance a functional cure for Type 1 Diabetes, marking a significant advancement in diabetes treatment.
- Integration of Clinical Experience: Eledon's clinical experience with over 100 transplant patients will provide crucial clinical data and insights for the development of NCEL-101, potentially streamlining the regulatory pathway and accelerating the product's market entry.
- Enhanced Immune Modulation: The immune modulation component of NCEL-101 is designed to improve cell durability and graft survival, with expectations to match outcomes seen with donor human islets, thereby enhancing treatment efficacy and addressing market demand for functional insulin-producing cells.
- Strategic Milestone: NewcelX's Chief Scientific Officer stated that this collaboration not only enhances the company's clinical execution capabilities but also broadens partnerships with leaders in immune biology and transplant medicine, which is expected to accelerate clinical project advancement and increase visibility among investors.
See More
NewcelX Collaborates with Eledon to Advance Diabetes Treatment
- Collaborative Research Agreement: NewcelX has signed a collaboration agreement with Eledon to integrate its lead product NCEL-101 with Eledon's anti-CD40L monoclonal antibody tegoprubart, aiming to advance a functional cure for Type 1 Diabetes, which is expected to accelerate clinical timelines and optimize regulatory pathways.
- Integration of Clinical Experience: Eledon's clinical experience with over 100 transplant patients provides crucial data support for the development of NCEL-101, which not only enhances the efficacy of cell replacement therapies but may also streamline the regulatory approval process, thereby expediting the product's market entry.
- Core Product Positioning: NCEL-101, as NewcelX's core therapeutic product, aims to address the shortage of functional insulin-producing cells through scalable, off-the-shelf manufacturing, with the integration of immune modulation intended to enhance cell survival and durability, thereby improving treatment outcomes.
- Strategic Milestone: NewcelX's Chief Scientific Officer Michel Revel stated that this collaboration marks an important strategic milestone for the company in executing clinical programs, and is expected to enhance partnerships with leaders in immune biology and transplant medicine, ultimately driving long-term shareholder value.
See More
Eledon Pharmaceuticals Presents 24-Month Data on Tegoprubart, Showing Significant eGFR Improvement
- Clinical Trial Results: Eledon presented 24-month follow-up data from eight patients at the 2026 American Society of Transplant Surgeons Winter Symposium, showing a significant increase in eGFR from 67.0 mL/min/1.73 m² at 12 months to 74.2 mL/min/1.73 m², indicating the potential efficacy of tegoprubart in kidney transplantation.
- Safety Assessment: Throughout the study, there were no episodes of biopsy-proven acute rejection, graft loss, death, or new-onset diabetes, further validating the safety and tolerability of tegoprubart, which enhances its market prospects.
- Academic Presentation Schedule: The study's poster will be presented during the poster session on January 23, 2026, from 5:45 to 7:15 PM, providing attendees with an opportunity to gain deeper insights into the drug, potentially attracting investor interest.
- Company Background: Eledon is a clinical-stage biotechnology company focused on developing immune-modulating therapies, with tegoprubart as its lead candidate, targeting CD40L's high affinity, which offers broad therapeutic potential in areas such as kidney transplantation.
See More
Avant Technologies Achieves 83% Insulin Independence Rate, Driving Investment Shift
- Clinical Trial Success: Avant Technologies achieved an 83% insulin independence rate in recent clinical trials, marking a significant shift towards functional cures that has attracted investment interest from the pharmaceutical industry, driving record valuations in 2025 M&A activity.
- Massive Market Potential: Analysts project the regenerative medicine market will surge from $37.98 billion in 2025 to $88.85 billion by 2030, highlighting strong demand for curative cell therapies, with Avant Technologies positioned at the forefront of this growth wave.
- Technological Breakthrough: Avant's collaboration with SGAustria to develop cell encapsulation technology protects genetically modified insulin-producing cells from immune rejection, addressing the long-standing issue of patients' reliance on immunosuppressive drugs, thereby enhancing treatment safety and efficacy.
- Global Health Market Opportunity: With 589 million people globally living with type 1 and insulin-dependent type 2 diabetes, projected to reach 853 million by 2050, Avant's technology is poised to capture a significant share of this vast market, driving future growth for the company.
See More
